Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Rhea-AI Summary

Lexeo Therapeutics (Nasdaq: LXEO) will host a virtual Key Opinion Leader event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Dec 9, 2025 at 3:00 PM ET. The session, titled “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy”, will feature Dr. Victoria Parikh, Associate Professor of Cardiovascular Medicine at Stanford and Director of the Stanford Center for Inherited Cardiovascular Disease, plus an expert clinician scientist who treats patients with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors may register via the company’s News & Events page, and a replay will be archived in Lexeo’s investor section after the event.

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22^nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9^th at 3 PM ET.

The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the News & Events page on Lexeo’s website. A replay will be archived on the investor section of Lexeo’s website following the event.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

FAQ

When is the Lexeo (LXEO) virtual event at the 22nd CVCT Forum?

The event is scheduled for Tuesday, December 9, 2025 at 3:00 PM ET.

How can investors register for Lexeo's (LXEO) Dec 9, 2025 CVCT virtual session?

Investors can register via Lexeo's News & Events page on the company website.

Who will present for Lexeo (LXEO) at the CVCT Forum on Dec 9, 2025?

The session features Dr. Victoria Parikh, Associate Professor of Cardiovascular Medicine at Stanford, and an expert clinician scientist treating PKP2-ACM.

What is the topic of Lexeo's (LXEO) virtual CVCT presentation?

The presentation is titled “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy”.

Will Lexeo (LXEO) make a replay of the CVCT session available?

Yes, a replay will be archived in the investor section of Lexeo's website after the event.

Is the Lexeo (LXEO) CVCT session intended for clinicians or investors?

The session is a clinician-focused discussion but analysts and investors are invited to join via registration.